Table 1.
Characteristics of patients with stage IIB and III pancreatic ductal adenocarcinoma and histopathological findings for pancreatic specimens
| Without venous resection | SMV margin analysis | |||
|---|---|---|---|---|
| Stage IIB | Stage III | Stage IIB | Stage III | |
| Total | 290 | 215 | 127 | 198 |
| Sex | ||||
| Male | 160 (55.2) | 122 (56.7) | 65 (51.2) | 94 (47.5) |
| Female | 1230 (44.8) | 93 (43.3) | 62 (48.8) | 104 (52.5) |
| Age (years), median (i.q.r.) | 68 (61–74) | 68 (62–74) | 67 (63–74) | 69 (62–74) |
| Preoperative BMI (kg/m2), median (i.q.r.) | 24 (22–27) | 24 (22–28) | 24 (22–28) | 24 (22–28) |
| Unknown | 65 (22.4) | 51 (17) | 16 (12.6) | 25 (12.3) |
| ASA grade | ||||
| I–II | 219 (75.5) | 157 (73.0) | 97 (76.4) | 148 (74.7) |
| III–IV | 70 (24.1) | 56 (26.0) | 29 (22.8) | 48 (24.2) |
| Unknown | 1 (0.3) | 2 (0.9) | 1 (0.8) | 2 (1.0) |
| Preoperative CA19-9 (kU/l), median (i.q.r.) | 140 (32–530) | 143 (38–624) | 112 (27–498) | 153 (34–660) |
| Unknown | 82 (28.3) | 59 (20) | 14 (11) | 28 (13.9) |
| Type of surgery | ||||
| Pancreatoduodenectomy | 235 (81.0) | 202 (94) | 120 (94.5) | 178 (89.9) |
| Distal pancreatectomy | 38 (13.1) | 6 (2.8) | 3 (2.4) | 7 (3.5) |
| Total pancreatectomy | 17 (5.9) | 7 (3.3) | 4 (3.1) | 13 (6.6) |
| Venous resection | NA | NA | 40 (31.5) | 107 (54.0) |
| Adjuvant therapy | 193 (66.6) | 127 (59.1) | 93 (73.2) | 128 (64.6) |
| Unknown | 26 (9.0) | 25 (11.6) | 16 (12.5) | 17 (8.4) |
| Tumour size (mm), median (i.q.r.) | 30 (25–40) | 30 (25–40) | 30 (21–35) | 33 (25–40) |
| Unknown | 10 (3.4) | 5 (1.7) | 1 (0.78) | 3 (1.5) |
| T stage | ||||
| T1–2 | 199 (68.6) | 146 (67.9) | 101 (79.5) | 129 (63.9) |
| T3 | 91 (31.4) | 69 (32.1) | 22 (17.3) | 67 (33.8) |
| Unknown | 13 (4.5) | 5 (2.3) | 4 (3.1) | 5 (2.5) |
| Differentiation stage | ||||
| 1–2 | 171 (59.2) | 128 (59.5) | 74 (58.1) | 120 (60.6) |
| 3–4 | 109 (37.7) | 76 (35.3) | 46 (36.5) | 73 (36.9) |
| Unknown | 9 (3.1) | 11 (5.1) | 6 (4.8) | 5 (2.5) |
| Number of harvested lymph nodes, median (i.q.r.) | 22 (16–32) | 22 (15–31) | 24 (16–32) | 25 (19–37) |
| Perineural invasion | 229 (79.0) | 188 (87.4) | 114 (89.8) | 180 (90.8) |
| Unknown | 12 (4.2) | 7 (3.2) | 3 (2.4) | 4 (2.0) |
| Angioinvasion | 144 (49.7) | 162 (75.3) | 73 (57.5) | 134 (67.7) |
| Unknown | 29 (10.0) | 22 (10.2) | 14 (11.0) | 17 (8.6) |
| Minimum reported margin | ||||
| Margin 0 mm | 55 (19.0) | 77 (35.8) | NA | NA |
| Unknown | 23 (7.9) | 16 (7.4) | – | – |
| Margin >0.5 mm | 186 (64.1) | 97 (45.1) | NA | NA |
| Unknown | 20 (6.9) | 16 (7.4) | – | – |
| Margin >1 mm | 97 (33.4) | 77 (35.8) | NA | NA |
| Unknown | – | – | – | – |
| Margin >2 mm | 38 (13.1) | 18 (8.4) | NA | NA |
| Unknown | 40 (13.8) | 51 (23.7) | – | – |
| SMV margin analysis | ||||
| SMV margin >0.5 mm | NA | NA | 46 (36.2) | 41 (20.7) |
| SMV margin ≤0.5 mm | NA | NA | 40 (31.5) | 50 (25.3) |
| No cancer in the vein specimen | NA | NA | 16 (12.6) | 37 (18.7) |
| Cancer in the vein specimen | NA | NA | 25 (19.7) | 70 (35.4) |
Values are n (%) unless otherwise indicated. i.q.r., interquartile range; NA, not available; CA19-9, carbohydrate antigen 19-9; SMV, superior mesenteric vein.